ERBB2 and breast carcinoma: Trastuzumab (Herceptin®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) is an anti-HER2 monoclonal antibody with proven survival benefits in the treatment of women with HER2-positive metastatic breast cancer (MBC) [7–11] and early breast cancer (EBC) [12–15].